Public trial registry of the CCC-Munich

Trial WO40242/ IMvoke010

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
WO40242/ IMvoke010
World
Full title
:

A PHASE III, MULTIZENTRUM, RANDOMISIERT,
DOPPELBLINDE, PLACEBO-KONTROLLIERTE STUDIE
VON ATEZOLIZUMAB (ANTI PD-L1 ANTIKĂ–RPER) AS
ADJUVANTE THERAPIE NACH DEFINITIVER LOKALER
THERAPIE BEI PATIENTEN MIT HOHEM RISIKO
LOKAL FORTGESCHRITTENE PLATTENZELLEN
KARZINOM VON KOPF UND HALS

World
Description
:

This study will evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of atezolizumab compared with placebo as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (SCCHN).

World
EudraCT number
:
World
NCT number
:
World
Responsible organization
:
Klinik f.Strahlentherapie, Telefon: 089440074521
Indications
Classification Code Description
- C00-C14, C30.-,C33 Head and Neck tumors
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Double blinded
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Unknown
Initiiation & lock
World
Date of lock (planned / actual)
:
2026-07-03 / 2025-08-01
Therapy
World
Therapy line
:
1
Participants
Function Prename Surname Organization